Back to top

Analyst Blog

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext.  9339.

Athersys, Inc. (ATHX - Snapshot Report), a biotechnology company, is developing MultiStem for ulcerative colitis in collaboration with Pfizer Inc. (PFE - Analyst Report). A double-blind, placebo-controlled, phase II trial is ongoing with initial results expected in early 2014. MultiStem is also being evaluated for ischemic stroke (phase II, enrollment ongoing with initial results expected mid-2014). The company is planning to initiate a phase II study on MultiStem for the acute myocardial infarction indication and a phase II/III for graft-versus-host disease.

In order to fund its ongoing trials and potential expansion of certain trials, apart from working capital needs and general corporate purposes, Athersys has entered into agreements to sell common stock (10,000,000 shares) and warrants (to purchase up to 3,500,000 shares of common stock) with gross proceeds of $20.0 million.

The warrants include immediately exercisable Series A warrants (to buy up to 2,098,785 shares) and Series B warrants (up to 1,401,215 shares), which will be non-exercisable for six months.  The warrants, which were offered for a purchase price of $2.00, have an exercise price of $2.50 per share. Both Series A warrants and Series B warrants are set to expire on Mar 31, 2015.

Institutional investors who have already invested in the company comprise the majority of the participants in the offering, which is due to close on Dec 3, 2013.

Athersys carries a Zacks Rank #3 (Hold). However, some better-ranked stocks include Actelion Ltd. (ALIOF) and Jazz Pharmaceuticals (JAZZ - Analyst Report). Both stocks carry a Zacks Rank #1 (Strong Buy).

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
LAKE SHORE G LSG 0.75 +3.48%
ENLINK MIDST ENLC 36.68 +2.69%
BNC BANCORP BNCN 17.47 +2.40%
EXTERRAN HLD EXH 45.03 +1.97%
SMITH & SWHC 14.52 +1.83%